Macquarie Group LTD Exelixis, Inc. Transaction History

Macquarie Group LTD

$87.4 Billion
Q1 2024

A detailed history of Macquarie Group LTD transactions in Exelixis, Inc. stock. As of the latest transaction made, Macquarie Group LTD holds 526,956 shares of EXEL stock, worth $11.8 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

526,956

Holding current value

$11.8 Million

% of portfolio

0.01%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$20.17 - $23.93 $10.6 Million - $12.6 Million	526,956 New	526,956 $12.5 Million
Q3 2023 Nov 14, 2023	SELL	$19.04 - $22.74 $1.13 Million - $1.35 Million	-59,435 Reduced 55.95%	46,800 $1.02 Million
Q2 2023 Aug 14, 2023	SELL	$18.17 - $20.48 $3.71 Million - $4.18 Million	-204,221 Reduced 65.78%	106,235 $2.03 Million
Q1 2023 May 15, 2023	BUY	$16.3 - $19.41 $1.68 Million - $2 Million	102,835 Added 49.53%	310,456 $6.03 Million
Q4 2022 Feb 21, 2023	SELL	$14.96 - $17.39 $114,563 - $133,172	-7,658 Reduced 3.56%	207,621 $3.33 Million

Q3 2022 Nov 14, 2022	BUY	$15.68 - $22.27 $361,392 - $513,278	23,048 Added 11.99%	215,279 $3.44 Million
Q2 2022 Aug 15, 2022	BUY	$17.44 - $23.16 $3.18 Million - $4.22 Million	182,235 Added 1823.08%	192,231 $4 Million
Q4 2021 Feb 11, 2022	SELL	$15.84 - $21.88 $11,658 - $16,103	-736 Reduced 6.86%	9,996 $183,000
Q3 2021 Nov 12, 2021	BUY	$16.3 - $21.14 $61,027 - $79,148	3,744 Added 53.58%	10,732 $227,000
Q2 2021 Aug 13, 2021	SELL	$17.95 - $25.56 $46,418 - $66,098	-2,586 Reduced 27.01%	6,988 $127,000
Q1 2021 May 14, 2021	SELL	$20.53 - $25.22 $55,102 - $67,690	-2,684 Reduced 21.9%	9,574 $216,000
Q3 2020 Nov 13, 2020	BUY	$20.67 - $26.94 $7,482 - $9,752	362 Added 3.04%	12,258 $300,000
Q2 2020 Aug 11, 2020	BUY	$16.46 - $27.42 $21,332 - $35,536	1,296 Added 12.23%	11,896 $282,000
Q2 2019 Aug 14, 2019	BUY	$18.93 - $24.75 $200,658 - $262,350	10,600 New	10,600 $227,000
Q4 2018 Feb 15, 2019	SELL	$13.65 - $21.8 $20.4 Million - $32.6 Million	-1,495,783 Closed	0 $0
Q3 2018 Nov 15, 2018	SELL	$15.87 - $22.4 $32.7 Million - $46.1 Million	-2,057,631 Reduced 57.91%	1,495,783 $26.5 Million
Q2 2018 Aug 14, 2018	BUY	$18.56 - $22.45 $29.1 Million - $35.2 Million	1,566,890 Added 78.88%	3,553,414 $76.5 Million
Q1 2018 May 11, 2018	BUY	$22.15 - $31.89 $10 Million - $14.4 Million	453,105 Added 29.55%	1,986,524 $44 Million
Q4 2017 Feb 15, 2018	BUY	$24.23 - $30.93 $6.23 Million - $7.95 Million	256,966 Added 20.13%	1,533,419 $46.6 Million
Q3 2017 Nov 08, 2017	BUY	$23.35 - $29.24 $29.8 Million - $37.3 Million	1,276,453	1,276,453 $30.9 Million

Others Institutions Holding EXEL

# of Institutions

459

Shares Held

246M

Call Options Held

1.7M

Put Options Held

1.02M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $7.23B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Macquarie Group LTD with notifications on news.

Account

Macquarie Group LTD Exelixis, Inc. Transaction History